Kevin J. Appelbaum - Mar 31, 2022 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Mark Heinen, Attorney-in-Fact for Kevin J. Appelbaum
Stock symbol
BTTX
Transactions as of
Mar 31, 2022
Transactions value $
$4,921
Form type
4
Date filed
4/4/2022, 04:27 PM
Previous filing
Dec 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock +Buy $4,921 +2,500 +66.67% $1.97 6,250 Mar 31, 2022 Direct F1
holding BTTX Common Stock 2,406,719 Mar 31, 2022 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) +Grant/Award $0 +235,000 $0.00 235,000 Apr 1, 2022 Common Stock 235,000 $1.97 Direct F3

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.96 to $1.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 These shares are owned directly by Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated May 16, 2020, as amended (the "Trust"), and indirectly by Mr. Appelbaum as trustee of the Trust. Mr. Appelbaum is an officer, director and ten percent owner of the Issuer.
F3 The stock option vests as to 1/4 of the shares subject to the stock option on April 1, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on April 1, 2022.